MNDL Bio

Executive Summary

MNDL Bio is an Israeli AI-driven biotech platform that specializes in designing host-optimized DNA constructs to enhance recombinant protein expression across multiple systems. By leveraging proprietary biophysical models and machine learning, the company delivers synthesis-ready whole-construct DNA sequences that preserve the target protein's amino-acid sequence while improving yield, stability, and scalability. Founded in 2020 and operating with a team of 10-50 employees, MNDL Bio targets biologics developers, industrial enzyme producers, and synthetic biology research groups. Its platform approach aims to reduce development timelines and costs for protein production, addressing key bottlenecks in biomanufacturing. While the company is still in the platform stage and has not disclosed funding or valuation, its AI-first methodology positions it to compete in the rapidly growing synthetic biology and enzyme engineering markets. The company's success hinges on validating its technology through partnerships and securing growth capital to expand its customer base and platform capabilities.

Upcoming Catalysts (preview)

• Q3 2026Series A Funding Announcement70% success
• Q4 2026Commercial Partnership with Major Biologics Developer60% success
• Q1 2027Launch of Enhanced AI Platform with Expanded Host Systems50% success